doi: 10.1056/NEJMoa1607141 43 MarsoS
GLP-1 Agonists Market Size, Share & Trends Analysis Report By Product (Branded GLP-1 Agonists, Dual / Triple, Biosimilars & Generic GLP-1 Agonists Agonists), By Indication (Type 2 Diabetes Mellitus, Obesity / Overweight Management, Cardiovascular & Metabolic Related Indications, Other Emerging Indications (e.g., NASH, Alzheimers-related)), By Route of Administration, By Distribution Channel, By Region and By Segments Forecasts, 2025-2034 GLP-1 Agonists Market Size is valued at USD 43.1 Bn in 2024 and is predicted to reach USD 260.1 Bn by the year 2034 at an 19.9% CAGR during the forecast period for 2025-2034
Injection site reactions Redness, itching, swelling, and minor bruising occur in approximately 1.4% of semaglutide users and 2.4% of tirzepatide users
For example, if you start at 250 pounds, this could translate to a loss of approximately 37 to 55 pounds in a year and a half
The 3.8-point gain is attributed to growing adoption in clinical and home-based use cases, where cost efficiency and dosing flexibility are critical
Retatrutide is a next-generation triple-agonist weight loss peptide that simultaneously activates GLP-1, GIP, and glucagon receptors
